Pharmacokinetic Variability in Pediatrics and Intensive Care: Toward a Personalized Dosing Approach
DOI:
https://doi.org/10.18433/jpps30082Abstract
Providing a safe and efficacious drug therapy for large and often heterogeneous populations is a challenging objective in clinical drug development and routine clinical practice. It has been known for years that the optimum dose required for many therapeutic agents among individuals is quite variable. A wide interindividual pharmacokinetic variability was described in clinically relevant populations such as pediatrics and critically ill patients. The aim of this article was to present the main individual factors influencing variability in these two populations and their applications. Growth and development are two specific features of children that are not observed in adults. And critically ill patients have a much higher level of sickness severity that is associated with profound pathophysiological changes. These particular features could lead to difficulties to attain therapeutic targets. Nonlinear mixed effects modeling is a common approach to identify unexplained population variability. This approach is often applied to evaluate and optimize drug therapy in particular populations. Numerous studies have been conducted in these two specific populations to characterize pharmacokinetic parameters and to identify individual factors influencing variability. Size, age and organ function appeared to be the main factors influencing pharmacokinetics in pediatrics. Factors influencing pharmacokinetics in critically ill patients were mainly cardiovascular system, organ dysfunction and organ support. Dosage individualization seems to be a key issue to optimize drug treatment in these specific populations. Clinically utility and safety of a model-based personalized drug therapy has been demonstrated for vancomycin in pediatrics. Many programs were available to optimize drug regimens, especially for antibiotic drugs in critically ill patients. This innovative personalized dosing approach is a promising way to optimize drug therapy in clinically relevant populations, such as pediatrics and critically ill patients.Downloads
References
Lu AYH. Drug-Metabolism Research Challenges in the New Millennium: Individual Variability in Drug Therapy and Drug Safety. Drug Metab Dispos. 1998 December 1, 1998; 26(12):1217–22. PMID: 9860931
Lippert J, Brosch M, von Kampen O, Meyer M, Siegmund HU, Schafmayer C, et al. A Mechanistic, Model-Based Approach to Safety Assessment in Clinical Development. CPT: pharmacomet syst pharmacol. 2012; 1:e13
Lu AYH. Drug-Metabolism Research Challenges in the New Millennium: Individual Variability in Drug Therapy and Drug Safety. Drug Metab Dispos. 1998 December 1, 1998; 26(12):1217–22. PMID: 9860931
Box, G.E.P & Draper, N.R. Empirical model-building and response surface (John Wiley & Sons, Inc. New York, 1986.
Sheiner LB, Rosenberg B, Melmon KL.Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972 Oct;5(5):411-59
Rowland M, Tozer TN. Clinical pharmacokinetics/pharmacodynamics. Philadelphia: Lippincott Williams and Wilkins, 2005
Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981 Nov-Dec;6(6):429-53
Anderson GD and Lynn AM. Optimizing pediatric dosing: A developmental pharmacologic approach. Pharmacotherapy 2009; 29(6): 680-90
Anderson BJ. My child is unique;the pharmacokinetics are universal. Paediatr Anaesth 2012; 22(6): 530-8.
Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL and Jacobs F. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010;14(2):R53
van der Poll T. Immunotherapy of sepsis. Lancet Infect Dis. 2001 Oct;1(3):165-74. Review.
Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K; EPIC II Group of Investigators.International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009 Dec 2;302(21):2323-9. doi: 10.1001/jama.2009.1754.
Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008; 47: 231–243.
Marsot A, Boulamery A, Bruguerolle B, Simon N. Population pharmacokinetic analysis during the first two years of life: an overview. Clinical Pharmacokinetics 2012; 51(12):787-98
Kearns GL and Reed MD. Clinical pharmacokinetics in infants and children. A reappraisal. Clin Pharmacokinet. 1989; 17: 29-67
Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24(1): 25–36
Neville KA, Becker ML, Goldman JL et al. Developmental pharmacogenomics. Pediatr Anesth 2011; 21: 255–265
Van Dalen R, Vree TB. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med. 1990; 16(3):S235-8
Oparaoji EC, Cornwell EE 3rd, Hekmat E, Lum Cheong R, Adir JS and Siram S. Aminoglycoside volume of distribution in postoperative patients with septic shock. Clin Pharm. 1993; 12(2):131-134
Felton TW, Hope WW, Roberts JA. How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it ? Diagnostic Microbiology and Infectious Disease 2014; 79:441-447
Di Giantomasso D, May CN, BellomoR. Vital organ blood flow during hyperdynamic sepsis. Chest. 2003; 124(3):1053-9
Leroux S, Jacqz-Aigrain E, Biran V, Lopez E, Madeleneau D, Wallon C, Zana-Taïeb E, Virlouvet AL, Rioualen S, Zhao W. Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2039-42. doi: 10.1128/AAC.02214-15. Print 2016 Apr
Marsot A, Guilhaumou R, Riff C, Blin O. Amikacin in critically ill patients: A review from population pharmacokinetics analysis. Clinical Pharmacokinetics 2017 Feb; 56(2):127-138. doi:10.1007/s40262-016-0428-x
Tsai D, Lipman J, Roberts JA. Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill. Curr Opin Crit Care. 2015 Oct;21(5):412-20. doi: 10.1097/MCC.0000000000000229. Review.
Fuchs A, Csajka C, Thoma Y, Buclin T, WidmerN. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet 2013; 52: 9-22
Downloads
Published
How to Cite
Issue
Section
License
This is an open access journal with free of charge non-commercial download. At the time of submission, authors will be asked to transfer the copyright to the accepted article to the Journal of Pharmacy and Pharmaceutical Sciences. The author may purchase the copyright for $500 upon which he/she will have the exclusive copyright to the article. Nevertheless, acceptance of a manuscript for publication in the Journal is with the authors' approval of the terms and conditions of the Creative Commons copyright license Creative Common license (Attribution-ShareAlike) License for non-commercial uses.
CLOCKSS system has permission to collect, preserve, and serve this Archival Unit.
